[May 26, 2016]

Global Guillain-Barre Syndrome Pipeline Report 2016 - Review of 4 Companies & Drug Profiles - Research and Markets

Research and Markets has announced the addition of the "Guillain-Barre Syndrome - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Guillain-Barre Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Guillain-Barre Syndrome and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipeines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

1. Introduction
2. Guillain-Barre Syndrome Overview
3. Therapeutics Development
4. Pipeline Products for Guillain-Barre Syndrome - Overview
5. Pipeline Products for Guillain-Barre Syndrome - Comparative Analysis
6. Guillain-Barre Syndrome - Therapeutics under Development by Companies
7. Guillain-Barre Syndrome - Therapeutics under Investigation by Universities/Institutes
8. Guillain-Barre Syndrome Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Guillain-Barre Syndrome - Products under Development by Companies
13. Guillain-Barre Syndrome - Products under Investigation by Universities/Institutes
14. Guillain-Barre Syndrome - Companies Involved in Therapeutics Development

• Akari Therapeutics, Plc
• Alexion Pharmaceuticals, Inc.
• Regenesance BV
• Takeda Pharmaceutical Company Limited

For more information visit http://www.researchandmarkets.com/research/5xcrzr/guillainbarre

View source version on businesswire.com: http://www.businesswire.com/news/home/20160526006035/en/

[ Back To TMCnet.com's Homepage ]